



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Wang et al.  
SERIAL NUMBER : 10/671,326 EXAMINER : Nyemah Grazier  
FILING DATE : September 25, 2003 ART UNIT : 1626  
FOR : BIFUNCTIONAL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Wang et al.  
U.S.S.N.: 10/671,326

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 26505-513.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529  
Heidi A. Erlacher, Reg. No. 45,409  
Attorney(s) for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
Address all written correspondence to  
**Customer no.: 30623**  
Tel: (617) 542-6000  
Fax: (617) 542-2241

TRA 2076017v1

Express Mail No.: EV463104507US  
Date of Deposit: September 29, 2005

Page 1 of 1  
Attorney Docket No.: 26505-513 (RIB-007)


Please type a plus sign (+) in this box

[+]

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



Modified Form 1449/PTO		Application Number	10/671,326
		Filing Date	September 25, 2003
		First Named Inventor	Wang
		Group Art Unit	1626
		Examiner Name	Nyeemah Grazier
		Attorney Docket Number	26505-513 (RIB-007)

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
---------------	----------	--------------------------	------------	-------------------------------------	-------	-----------	----------------------------

**U.S. PUBLISHED APPLICATION DOCUMENTS**

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
---------------	----------	--------------------------------	----------------	-------------------------------------	-------	-----------	----------------------------

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B50	WO 02/081470 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	10/17/02	
	B51	WO 03/035648 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	05/01/03	
	B52	WO 03/072575 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	09/04/03	
	B53	WO 2004/056817 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07/08/04	
	B54	WO 2004/056818 A1	ASTRAZENECA AB; ASTRAZENECA UK LIMITED	07/08/04	
	B55	WO 2004/078770 A1	RIB-X PHARMACEUTICALS, INC.	09/16/04	
	B56	WO 2005/042554 A1	RIB-X PHARMACEUTICALS, INC.	05/12/05	
	B57	WO 2005/049632 A1	RIB-X PHARMACEUTICALS, INC.	06/02/05	
	B58	WO 2005/085266 A2	RIB-X PHARMACEUTICALS, INC.	09/15/05	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C18	Gregory et al. <i>J. Med. Chem.</i> , 32:1673-1681 (1989)

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.